# Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

> **NCT00311376** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 416 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **BIOLOGICAL:** botulinum toxin Type A (200U)
- **BIOLOGICAL:** botulinum toxin Type A (300U)
- **OTHER:** Normal Saline (Placebo); botulinum toxin Type A (200U)
- **OTHER:** Normal Saline (Placebo); botulinum toxin Type A (300U)

## Key facts

- **NCT ID:** NCT00311376
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2015-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00311376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00311376, "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00311376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*